Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis
Background: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. Method: A literature search was performed in six databa...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-09-01
|
| Series: | Integrative Medicine Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213422020301098 |
| _version_ | 1818159863398662144 |
|---|---|
| author | Wentai Pang Zhi Liu Nan Li Yuyun Li Fengwen Yang Bo Pang Xinyao Jin Wenke Zheng Junhua Zhang |
| author_facet | Wentai Pang Zhi Liu Nan Li Yuyun Li Fengwen Yang Bo Pang Xinyao Jin Wenke Zheng Junhua Zhang |
| author_sort | Wentai Pang |
| collection | DOAJ |
| description | Background: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. Method: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. Result: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. Conclusion: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required. |
| first_indexed | 2024-12-11T15:52:44Z |
| format | Article |
| id | doaj.art-f342db5ef8ab48569a7c6c4065d27acc |
| institution | Directory Open Access Journal |
| issn | 2213-4220 |
| language | English |
| last_indexed | 2024-12-11T15:52:44Z |
| publishDate | 2020-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Integrative Medicine Research |
| spelling | doaj.art-f342db5ef8ab48569a7c6c4065d27acc2022-12-22T00:59:32ZengElsevierIntegrative Medicine Research2213-42202020-09-0193100477Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysisWentai Pang0Zhi Liu1Nan Li2Yuyun Li3Fengwen Yang4Bo Pang5Xinyao Jin6Wenke Zheng7Junhua Zhang8Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaCorresponding author at: Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, No. 10 Poyanghu Road., Jinghai District, Tianjin 301617, China.; Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaBackground: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. Method: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. Result: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. Conclusion: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required.http://www.sciencedirect.com/science/article/pii/S2213422020301098Coronavirus disease 2019Integrative medicineChinese medical drugSystematic reviewCore outcome setMeta analysis |
| spellingShingle | Wentai Pang Zhi Liu Nan Li Yuyun Li Fengwen Yang Bo Pang Xinyao Jin Wenke Zheng Junhua Zhang Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis Integrative Medicine Research Coronavirus disease 2019 Integrative medicine Chinese medical drug Systematic review Core outcome set Meta analysis |
| title | Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis |
| title_full | Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis |
| title_fullStr | Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis |
| title_full_unstemmed | Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis |
| title_short | Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis |
| title_sort | chinese medical drugs for coronavirus disease 2019 a systematic review and meta analysis |
| topic | Coronavirus disease 2019 Integrative medicine Chinese medical drug Systematic review Core outcome set Meta analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2213422020301098 |
| work_keys_str_mv | AT wentaipang chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT zhiliu chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT nanli chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT yuyunli chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT fengwenyang chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT bopang chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT xinyaojin chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT wenkezheng chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis AT junhuazhang chinesemedicaldrugsforcoronavirusdisease2019asystematicreviewandmetaanalysis |